Two Arm Cuff Methods for Watching Seizures During Electroconvulsive Therapy

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 65 who are scheduled for elective electroconvulsive therapy (ECT). It compares two ways of watching for seizure movements during ECT.

Age

18 to 65 years

Sex

All sexes can join.

Disease stage

Patients scheduled for elective ECT, with ASA physical status I to III. The trial lists major depressive disorder, bipolar disorder and schizophrenia.

Main reasons for not taking part

• Known neuromuscular disease, for example myasthenia gravis
• Known allergy to sugammadex, rocuronium, ketamine, dexmedetomidine or propofol
• Venous insufficiency, lymphedema or active infection in the arms
• Severe cardiovascular instability

The registry criteria, word for word

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

• Are you between 18 and 65 years old?YesNo

What the trial wants to find out

This prospective, open-label clinical trial aims to compare a novel "Venous Tourniquet with Regional Low-Dose Sugammadex" method against the gold standard "Arterial Tourniquet" (Isolated Forearm Technique - IFT) for monitoring motor seizure activity during Electroconvulsive Therapy (ECT). Using a within-subject (intra-individual) design, each of the 40 enrolled patients will receive an arterial tourniquet on one arm and a venous tourniquet on the other arm simultaneously. The study will evaluate clinical efficacy in observing motor seizures, comparing the duration and visibility between the two limbs of the same patient, as well as assessing overall patient comfort and hemodynamics.

The group in the trial

• All ECT PatientsTreatment being tested

  All enrolled patients will receive both interventions simultaneously. An arterial tourniquet will be applied to one limb (control), and a venous tourniquet followed by regional sugammadex will be applied to the contralateral limb (experimental) during the same ECT session.

  Treatment: Device: Arterial Tourniquet, Device: Venous Tourniquet, and Sugammadex